Urinary β2-microglobulin as an early marker of infantile enterovirus and human parechovirus infections

Junji Azuma, MDa*, Takehisa Yamamoto, MD, PhDb, Mihoko Sakurai, MAD, Ryuko Amou, MAD, Chieko Yamada, MAD, Kazuhisa Hashimoto, MDb, Satomi Kajita, MDc, Kyoko Yamamoto, MDb, Eri Kijima, MAD, Yoshimi Mizoguchi, MAD, Keiko Nakata, PhDa, Tunesuke Shimotsuji, MD, PhDb, Keiichi Ozono, MD, PhDb

Abstract
Enterovirus and human parechovirus (HPeV) are RNA viruses belonging to the family Picornaviridae that frequently infect infants. These infections show a wide variety of clinical manifestations, from mild to severe. However, there are no known early clinical markers for diagnosis and prediction of disease severity. The aim of this study was to examine the clinical utility of urinary beta 2-microglobulin (β2MG) for the early detection and prognosis of infantile enterovirus and HPeV infections.

This retrospective study included 108 full-term infants younger than 60 days of age, including 15 with enterovirus or HPeV-3 (enterovirus/HPeV-3), 22 with respiratory syncytial virus (RSV), and 24 with bacterial infections. Laboratory data and clinical characteristics were compared among these 3 groups. Of the 15 patients with enterovirus/HPeV-3, 6 were treated with intravenous immunoglobulin (IVIG subgroup) because of severe clinical conditions.

Urinary β2MG to creatinine ratio (β2MG/Cr) was significantly higher in the enterovirus/HPeV-3 group compared to bacterial and RSV infection groups (both P<.001). In the enterovirus/HPeV-3 group, mean peak urinary β2MG/Cr was observed on day 1 or 2. Urinary β2MG/Cr values were significantly higher in the IVIG subgroup than the non-IVIG subgroup (P<.001).

Increased urinary β2MG/Cr in early-stage infection may be a useful clinical marker for the detection and prediction of infantile enterovirus and HPeV infection severity.

Abbreviations: β2MG = beta 2-microglobulin, AST = aspartate aminotransferase, CK = creatine kinase, Cr = creatinine, CRP = C-reactive protein, HPeV = human parechovirus, IVIG = intravenous immunoglobulin, LDH = lactate dehydrogenase, MHC = major histocompatibility complex, PLT = platelets, rRT-PCR = real-time reverse transcriptase polymerase chain reaction, RSV = respiratory syncytial virus, VP = viral protein, WBC = white blood cells.

Keywords: enterovirus, human parechovirus, intravenous immunoglobulin, urinary β2 microglobulin

1. Introduction
The Picornaviridae family RNA viruses enterovirus and human parechovirus (HPeV) are frequent causes of febrile infections in infants.[1,2] Enterovirus and HPeV infections show a variety of clinical manifestations ranging from mild gastrointestinal symptoms to potentially fatal diseases such as meningitis and sepsis.[3,4] Therefore, the diagnosis and prediction of disease severity in the early stage of infection may aid in guiding therapeutic intervention to prevent the development of serious conditions, unnecessary treatments, and prolonged hospitalization. The gold standard for diagnosing enterovirus and HPeV infections is real-time reverse transcriptase polymerase chain reaction (rRT-PCR),[5] however, it is not a routine diagnostic procedure available in many clinical settings.

Beta 2-microglobulin (β2MG) is a low molecular weight protein that constitutes the light chain of class I major histocompatibility complex (MHC-I) proteins present on the surface of almost all nucleated cells.[6] Expression of MHC-I is particularly high on the surfaces of activated lymphocytes and macrophages during infection.[6,7] Increased serum β2MG has also been reported in several viral infections, suggesting utility as a marker of lymphocyte activation and associated immune reactions.[8–12] However, the clinical significance of β2MG and the implications of β2MG upregulation for viral infections remain unclear.

In this study, we examined the clinical utility and implications of urinary β2MG in infants with enterovirus, HPeV, and other viral or bacterial infections.

2. Patients and methods
2.1. Study population and sample collection
This retrospective study included 108 otherwise healthy full-term (37–41 weeks) infants younger than 60 days of age hospitalized for fever ≥ 37.8°C at Minho City Hospital between November 2014 and August 2017.
Sepsis workup and rapid viral testing were conducted in all the 108 patients based on the seasonal spread of respiratory syncytial virus (RSV), rotavirus, influenza, and adenosivirus infections. Among the cases in which these infections were excluded, those with suspicious clinical presentations were screened for enterovirus and HPeV by RT-PCR after obtaining oral informed consent from legal guardians. The ethics committee of Osaka Institute of Public Health approved the screening protocol. Control data were obtained from patients diagnosed with RSV infection by rapid viral testing and from patients with bacterial infections based on positive urine, serum, or cerebrospinal fluid culture or serum C-reactive protein (CRP) above 2mg/dL.

2.2. Clinical and laboratory data analysis
The clinical characteristics and laboratory data were examined and compared among the following patient groups: enterovirus or HPeV (enterovirus/HPeV), RSV, and bacterial infection. In addition, we compared maximum urinary β2MG to creatinine ratio (β2MG/Cr) among the enterovirus/HPeV cases and the other groups. The patients in the enterovirus/HPeV group were classified further according to intravenous immunoglobulin (IVIG) treatment into an IVIG subgroup (patients 1–6) and a non-IVIG subgroup (patients 7–15) for comparison of clinical characteristics and laboratory data. Laboratory data including white blood cells (WBCs), platelets (PLTs), aspartate aminotransferase (AST), creatine kinase (CK), lactate dehydrogenase (LDH), and CRP at the time of peak urinary β2MG/Cr were included in the analysis. Finally, ferritin levels were examined in the IVIG subgroup.

2.3. Screening and genotyping of enterovirus and HPeV based on the viral genome
The MagDEA Viral DNA/RNA 200(GC) kit (Precision System Science Co., Japan) was used for RNA extraction according to the manufacturer’s instructions. The RT-PCR screen for detection of enterovirus RNA[13] and HPeV RNA[14] was performed using StepOnePlus (Applied Biosystems, Foster City, CA). The samples were classified as genome-positive for enterovirus[13] or HPeV[14] according to the sequences of the enterovirus viral protein 4-2 region (VP4-2) and the HPeV VP1 region retrieved from GenBank using the Basic Local Alignment Search Tool (BLAST).

2.4. Urinalysis and urinary β2MG measurement
Urine samples were obtained by the usage of catheter or urine collection bags several times during hospitalization. Urine blood, glucose, protein, and uric acid were included in urinalysis for screening urinary system diseases. Urinary β2MG was determined by latex immunoassay (Wako, Osaka, Japan) and normalized to urinary Cr levels.

2.5. Statistical analysis
The differences among the enterovirus/HPeV, RSV, and bacterial infection groups were evaluated by the Kruskal–Wallis analysis followed by the Steel–Dwass test for pair-wise comparisons. The Mann–Whitney U test was used to compare the IVIG subgroup to the non-IVIG subgroup. However, given the small sample sizes, statistical power analysis was first employed to assess whether statistical significance was correct. JMP software version 12.0 (SAS Institute, Cary, NC) was used for all the statistical analyses except for statistical power analysis. A p value < .05 was accepted as significant. SPSS version 23.0 (IBM Corp, Armonk, NY) was used for statistical power analysis. Significance was considered correct when the power was 0.80 or higher.

3. Results
3.1. Detection of viral and bacterial pathogens
Of 108 patients examined, RSV was detected in 22 and bacterial infections in 24. Among the 24 patients with bacterial infections, urinary tract infections were found in 10, meningitis in 3, and other infections in 11 patients. Of the 20 patients evaluated by RT-PCR, 15 were positive for enterovirus or HPeV according to at least one throat swab, fecal sample, or serum sample. The detected viruses were coxsackievirus B5 in 5 patients, HPeV type 3 (HPeV-3, recently renamed parechovirus A3) in 4, echovirus 9 in 3, and echovirus 18, echovirus 25, and coxsackievirus B1 in 1 patient each. Of the remaining 47 patients, 4 were infected with rotavirus, 3 with influenza virus, and 1 each with adenosivirus and cytomegalovirus. No specific pathogen could be found in the other 38 patients.

3.2. Clinical characteristics of the patients with enterovirus or human parechovirus infections
Table 1 summarizes basic characteristics of patients with enterovirus or HPeV-3 infection. Viruses were detected in the fecal samples of all the patients, in throat swabs of 12 out of 15 patients, and in serum samples of 9 out of 12 patients. Rash and diarrhea were observed in 11 out of the 15 enterovirus/HPeV-3 patients. Abdominal distention was observed in 3 patients with HPeV-3 infection and 1 patient with echovirus 9 infection. In addition, apnea was observed in 2 patients with HPeV-3 infection. IVIG was administered to 6 patients because of poor general clinical condition. None of the patients with enterovirus or HPeV-3 infection had sequelae.

Maximum temperature and heart rate were significantly higher in the enterovirus/HPeV group compared to the bacterial and RSV infection groups (Table 2, Fig. 1A and B). Furthermore, the maximum temperature and respiratory rate were significantly higher and the duration of fever was significantly longer in the IVIG subgroup than the non-IVIG subgroup (Table 3).

3.3. Laboratory findings
Maximum urinary β2MG/Cr was significantly higher in the HPeV-3 infection group than the enterovirus group, and significantly higher in both enterovirus and HPeV-3 groups than the other groups (Table 2 and Fig. 1D and E). LDH levels were significantly higher in the enterovirus/HPeV group than in the RSV infection group (Fig. 1C). The WBC and CRP levels were significantly higher in the bacterial infection group than the enterovirus/HPeV and RSV infection groups (Table 2). In the enterovirus/HPeV group, the mean maximum urinary β2MG/Cr was observed on day 1 or 2 and tended to decrease gradually thereafter (Fig. 2A), a trend that was more marked in the IVIG subgroup (Fig. 2B). Both LDH and maximum urinary β2MG/Cr were significantly higher in the IVIG subgroup than the non-IVIG subgroup (Table 3). Evaluation of the laboratory data over time revealed that the highest mean AST, LDH, CK, and ferritin levels were observed on day 3 or 4 (Fig. 2C–F). In the enterovirus/HPeV
group, 2 patients exhibited elevated urinary glucose and one patient showed elevated urinary protein (patients 3 and 5).

4. Discussion
The current retrospective study revealed elevated urinary β2MG/Cr in infantile enterovirus and HPeV-3 infection patients compared to RSV and bacterial infection patients. Furthermore, early urinary β2MG/Cr elevation was even greater in more severe cases, suggesting utility as a marker of disease presence and severity.

MHC-I molecules are heterodimers of 2 polypeptide chains, α-microglobulin and β2MG. Newly synthesized MHC-I chains assemble with β2MG in the endoplasmic reticulum lumen and are transported to the external membrane. The primary function of MHC-I is to present exogenous antigens such as viral proteins to cytotoxic T cells. Consequently, β2MG is upregulated during the early stage of infection to enhance antigen presentation by MHC-I. Increased MHC-I expression leads to elevated serum β2MG levels because β2MG can dissociate from membrane-associated MHC-I. Serum β2MG is freely filtered through the glomerular basement membrane, and up to 99.9% of β2MG that passes through glomeruli is reabsorbed at proximal renal tubules. Therefore, urinary β2MG levels increase in renal tubular dysfunction or when serum β2MG levels rise above the threshold of tubular reabsorption. However, renal tubular dysfunction is unlikely to explain our findings. While the proximal tubule may be susceptible to hypoxia, only 2 patients with apnea in the enterovirus/HPeV group required oxygen administration during hospitalization. Furthermore, we did not

| Table 1 | Clinical characteristics and laboratory findings of the patients with enterovirus and human parechovirus. |
|---------|---------------------------------------------------------------------------------------------------|
| No. | Age, days | Sex | Virus | Isolation site | Maximum urinary β2MG/Cr (μg/gCr) | Maximum fever, °C | Minimum systolic blood pressure, mm Hg | Treatment | Fever duration, days |
|       |          |     |       |            |                            | heart rate, beats per minute, respiration rate, per minute | | | |
| 1 | 60/ male | HPeV3 | T(+), Fe(+), S(+)] | day 2 | 202760 | 40.6, 212, 62 | 76 | Days 2–3 IVIG | 5 | Rash, diarrhea, seizure, distended abdomen |
| 2 | 40/ female | HPeV3 | T(+), Fe(+), S(+)] | Day 2 | 195755 | 39.8, 204, 58 | 74 | Days 2–3 IVIG | 4 | Rash, diarrhea, distended abdomen |
| 3 | 18/ male | HPeV3 | T(+), Fe(+), S(+)] | Day 3 | 184525 | 39.8, 199, 60 | 70 | Days 1–2 IVIG | 4 | Rash, diarrhea, apnea, distended abdomen |
| 4 | 23/ male | E18 | T(–), Fe(+), S(–)] | Day 3 | 177780 | 39.9, 190, 56 | 70 | Day 4 IVIG | 5 | Rash, diarrhea |
| 5 | 6/ male | HPeV3 | T(+), Fe(+), S(+)] | Day 1 | 174400 | 38.5, 191, 58 | 74 | Day 4 IVIG | 4 | Rash, diarrhea, apnea |
| 6 | 10/ male | CVB5 | T(+), Fe(+), S(+)] | Day 7 | 73319 | 39.6, 200, 48 | 63 | Day 3 IVIG | 4 | Rash, diarrhea |
| 7 | 8/ female | CVB5 | T(+), Fe(+), S(+)] | Day 1 | 99718 | 38.7, 179.46 | 94 | 5 | Rash, diarrhea |
| 8 | 13/ male | CVB1 | T(+), Fe(+), S(+)] | Day 3 | 53340 | 39, 180, 57 | 84 | 4 | Rash |
| 9 | 29/ male | E25 | T(+), Fe(+), S(+)] | Day 3 | 42300 | 39.6, 185, 48 | 92 | 2 | Dianrea |
| 10 | 25/ female | E9 | T(+), Fe(+), S(–)] | Day 1 | 48533 | 38.5, 185, 44 | 90 | 3 | Diarrhea |
| 11 | 23/ male | E9 | T(+), Fe(+), S(–)] | Day 2 | 30486 | 39.1, 201, 44 | 74 | 3 | Rash, distended abdomen |

CVB = coxsackievirus B, E = echovirus, Fe = feces, HPeV = human parechovirus, MIG = intravenous immunoglobulin, n/d = not done, S = serum, T = throat swab, U-β2MG/Cr = urinary β2-microglobulin/creatinine. Day 1 indicates hospitalization date.

| Table 2 | Comparison of the clinical characteristics and laboratory findings among the groups of enterovirus or human parechovirus infections, bacterial infections, and respiratory syncytial virus infections. |
|---------|---------------------------------------------------------------------------------------------------|
| EnteroVirus/HPeV (n = 15) | Bacterial infections (n = 24) | Respiratory syncytial virus (n = 22) | P |
| Sex (male) | 10 (67) | 15 (63) | 12 (55) | .74 |
| Age, days | 23 (16–40) | 33 (20–51.8) | 41 (24–54) | .086 |
| Maximum temperature, °C | 39.5 (38.7–39.8) | 38.5 (37.9–39.1) | 38 (37.8–38.2) | < .001 |
| Maximum heart rate, beats per minute | 191 (185–204) | 180 (173–186.8) | 180.5 (175–186.3) | .009 |
| Maximum respiratory rate, times a minute | 50 (46–58) | 52 (46–50) | 49 (47–57) | .42 |
| WBC, /μL | 7,100 (6,000–9,800) | 12,650 (7,700–17,000) | 8,150 (6,900–8,875) | .005 |
| PLT, ×10^11/μL | 40.4 (31–45.4) | 42 (33.2–49.5) | 42 (34.8–48.5) | .64 |
| AST, IU/L | 36 (22–41) | 25 (20.3–33.8) | 27.5 (23.5–40) | .14 |
| LDH, IU/L | 306 (283–347) | 257 (239.3–322.3) | 271 (234.8–295.3) | .013 |
| CK, IU/L | 75 (51–113) | 82 (73–120) | 84 (63–99) | .35 |
| CRP, mg/dL | 0.25 (0.1–0.49) | 4.05 (2.9–6.6) | 0.13 (0.1–0.68) | < .001 |
| Maximum urinary β2MG/Cr, μg/gCr | 53,540 (37,467–177,780) | 8188 (1,470–33,925) | 15,430 (6,116–36,154) | < .001 |

AST = aspartate aminotransferase, CK = creatine kinase, CRP = C-reactive protein, HPeV = human parechovirus, LDH = lactate dehydrogenase, PLT = platelets, U-β2MG/Cr = urinary β2-microglobulin/creatinine, WBC = white blood cells. Values are expressed as medians (range) or numbers (%), unless otherwise indicated. Statistical analysis was performed using the Kruskal-Wallis test.

3
observe an increase in urinary glucose or uric acid levels indicative of proximal tubule dysfunction in most of the study cases. Thus, we suggest that elevated urinary β2MG levels reflect increased protein production for MHC-I-mediated antigen presentation.

In neonatal enterovirus infections, the initial sites of virus replication are the pharynx and terminal ileum. Replication gives rise to transient viremia, which leads to hematogenous spread of the virus to lymphoid tissue throughout the body, followed by viral replication at these sites and secondary viremia. These processes coincide with the onset of symptoms and result in viral spread throughout the entire body. Several studies have reported that the highest viral loads in blood occur in the early stage of enterovirus infection and decrease gradually thereafter. Low levels of maternal antibodies against enterovirus and HPeV-3 may allow for high viral replication in the early stage of infection. Of note, these changes in viral load paralleled the rise in urinary β2MG observed in study patients with enterovirus or HPeV-3 infection (Fig. 2A and B). In fact, β2MG was reported previously to be positively correlated with viral load in patients infected with human immunodeficiency virus or Epstein-Barr virus.

| (°C) | Temperature | (bpm) | Heart rate |
|------|-------------|-------|------------|
| 41   | BI EV/HPeV  | 220   | **          |
| 40.5 | BI EV/HPeV  | 220   | **          |
| 40   | RSV         | 220   | **          |
| 39.5 | BI EV/HPeV  | 220   | **          |
| 39   | RSV         | 220   | **          |
| 38.5 | BI EV/HPeV  | 220   | **          |
| 38   | RSV         | 220   | **          |
| 37.5 | BI EV/HPeV  | 220   | **          |
| 37   | RSV         | 220   | **          |

![Box-whisker plots for clinical markers](image)

**Figure 1.** Significant differences in clinical markers, including urinary beta 2-microglobulin to creatinine ratio, among patient groups with enterovirus or human parechovirus infection, bacterial infection, or respiratory syncytial virus infection. In box-whisker plots, box bottom and top indicate the first and third quartiles, respectively, and the band inside the box is the second quartile (median). Ends of the whiskers are minimum and maximum values, and cross marks indicate mean values. Groups were compared using the Steel-Dwass test. *P < .05; **P < .01; ***P < .001. BI = bacterial infections, EV = enterovirus, HPeV = human parechovirus, LDH = lactate dehydrogenase, Max = maximum, RSV = respiratory syncytial virus, U-β2MG/Cr = urinary beta 2-microglobulin to creatinine ratio.
The innate immune system is the first line of host defense against pathogens, and interferon-α signaling may be particularly important for responses to viral infections and upregulation of both β2MG and MHC-I. Furthermore, effective immunity against pathogens is dependent on the initial recognition of infectious agents. Increased levels of several cytokines/chemokines involved in the early detection of viral pathogens have been reported during both enterovirus and HPeV infections, although many types of inflammatory immune responses, including interleukin-6 and ferritin responses, differ between HPeV and enterovirus infections. Based on these findings, we suggest that the early rise in urinary β2MG/Cr during enterovirus and HPeV-3 infections may reflect increased viral load and the ensuing innate immune response.

Maximum urinary β2MG/Cr levels were significantly higher in the HPeV-3 group than the enterovirus group (Fig. 1E), and higher in both enterovirus and HPeV-3 groups compared to all other groups (Fig. 1D and E). Several factors might explain these observed differences in urinary β2MG/Cr levels in the present study. First, viral RNA concentrations tend to be higher during the early stage of infection. Therefore, we suggest that the marked elevation of urinary β2MG/Cr in the early stage of infection is a strong candidate indicator of disease severity and that early therapeutic intervention using IVIG may be effective for patients with clinically severe infantile enterovirus or HPeV-3 infection.

However, the increase in urinary β2MG/Cr may not be specific to enterovirus and HPeV-3 infections, but rather extend to other viral infection with viremia due to robust viral replication and ensuing strong immune responses. Thus, it may be possible to predict severe infantile viral infections based on high urinary β2MG/Cr elevation. In usual clinical settings, PCR is not a routine diagnostic procedure because it is not covered by medical insurance and is expensive. Consequently, measurement of urinary β2MG/Cr may be superior to PCR due to low cost, ease of performance, and noninvasiveness.

There were several inherent limitations in the present study. First, this was a retrospective case study. Second, the exact pathophysiology underlying the elevation in urinary β2MG/Cr levels during the early stage of infection remains unclear, although we suggest that the increase reflects viral load and the innate immune response against viral replication. Third, chemokine/chemokine levels and viral loads were not measured. Thus, further studies are necessary to clarify the relationships among β2MG, chemokines/chemokines, and viral load.

In conclusion, this retrospective analysis revealed that the increase in urinary β2MG/Cr may be a useful marker for infantile enterovirus and HPeV-3 infections. Additionally, an unusually large elevation in urinary β2MG/Cr in early-stage infantile enterovirus or HPeV-3 infection may be predictive of severe disease and an indicator for IVIG therapy.
Figure 2. Temporal differences in peak clinical parameters among infection groups. Day 1 indicates the day of hospitalization. See Figure 1 for box-whisker plot definitions. (A) Changes in U-β2MG/Cr levels among patients with enterovirus or human parechovirus infection. (B) U-β2MG/Cr changes in the intravenous immunoglobulin subgroup. (C–F) AST, CK, LDH, and ferritin level changes in the intravenous immunoglobulin subgroup. AST = aspartate aminotransferase, CK = creatine kinase, LDH = lactate dehydrogenase, U-β2MG/Cr = urinary beta 2-microglobulin/creatinine.
Acknowledgments
The authors would like to thank Enago (www.enago.jp) for the English language review.

Author contributions
Conceptualization: Junji Azuma.
Data curation: Junji Azuma, Mihoko Sakurai, Ryuko Amou, Chieko Yamada, Kazuhisa Hashimoto, Satomi Kajita, Kyoko Yamamoto, Eri Kijima, Yoshimi Mizoguchi, Keiko Nakata.
Formal analysis: Junji Azuma, Takehisa Yamamoto.
Funding acquisition: Keiko Nakata.
Investigation: Eri Kijima, Keiko Nakata.
Methodology: Takehisa Yamamoto, Eri Kijima, Yoshimi Mizoguchi, Keiko Nakata, Tunesuke Shimotsuji, Keichii Ozono.
Writing – original draft: Junji Azuma.
Writing – review & editing: Junji Azuma.

Junji Azuma orcid: 0000-0001-7667-2645.

References
[1] de Crom SC, Rossen JW, van Furth AM, et al. Enterovirus and parechovirus infection in children: a brief overview. Eur J Pediatr 2016;175:1023–9.
[2] Verboom-Maciolek MA, Krediet TG, Gerards LJ, et al. Severe neonatal parechovirus infection and similarity with enterovirus infection. Pediatr Infect Dis J 2008;27:241–5.
[3] Bracco S, Kapetanostкратski M, Sharland M, et al. Intensive care admissions for children with enterovirus and human parechovirus infections in the United Kingdom and The Republic of Ireland, 2010–2014. Pediatr Infect Dis J 2017;36:339–42.
[4] de Crom SC, Obihara CC, de Moor RA, et al. Prospective comparison of the detection rates of human enterovirus and parechovirus RT-qPCR and viral culture in different pediatric specimens. J Clin Virol 2015;68:449–54.
[5] Grey HM, Kulo RT, Colon SM, et al. The small subunit of HL-A antigens is beta2-microglobulin. J Exp Med 1973;138:1608–12.
[6] Vivian JP, Duncan RC, Berry R, et al. Killer cell immunoglobulin-like receptor 3DL1-mediated recognition of human leukocyte antigen B. Nature 2011;479:401–5.
[7] Lu X, Gibbs JS, Hickman HD, et al. Endogenous viral antigen processing generates peptide-specific MHC class I cell-surface clusters. Proc Natl Acad Sci U S A 2012;109:15407–12.
[8] Nесov-Ostojic J, Klinn I, Vujanic M, et al. Serum beta2-microglobulin as a marker of congenital toxoplasmosis and cytomegalovirus infection in preterm neonates. Neonatology 2008;94:183–6.
[9] Chipta P, Balehavasalam B, Pavannant T. Beta-2 microglobulin as an immunological marker to assess the progression of human immunodeficiency virus infected patients on highly active antiretroviral therapy. Clin Chim Acta 2011;412:1151–4.
[10] Berthea M, Forman DT. Beta-2 microglobulin: its significance and clinical usefulness. Ann Clin Lab Sci 1990;20:163–8.
[11] Kin K, Kasahara T, Itoh Y, et al. beta2-Microglobulin production by highly purified human T and B lymphocytes in cell culture stimulated with various mitogens. Immunochemistry 1979;36:47–54.
[12] Grywalska E, Rolinski J, Pasarski M, et al. High viral loads of Epstein–Barr virus DNA in peripheral blood of patients with chronic lymphocytic leukemia associated with unfavorable prognosis. PLoS One 2015;10: e0140178.
[13] Tapparel C, Cordey S, Van Belle S, et al. New molecular detection tools adapted to emerging rhinoviruses and enteroviruses. J Clin Microbiol 2009;47:1742–9.
[14] Nox WA, Maher K, Johansson ES, et al. Detection of all known parechoviruses by real-time PCR. J Clin Microbiol 2008;46:2519–24.
[15] Ishiko H, Shimada Y, Yonaha M, et al. Molecular diagnosis of human enteroviruses by phylogeny-based classification by use of the VP4 sequence. J Infect Dis 2002;185:744–54.
[16] Nox WA, Oberste MS, Pallansch MA. Sensitive, seminested PCR amplification of VP1 sequences for direct identification of all enterovirus serotypes from original clinical specimens. J Clin Microbiol 2006;44:692–704.
[17] Lankat-Buttgereit B, Tampe R. The transporter associated with antigen processing: function and implications in human diseases. Physiol Rev 2002;82:187–204.
[18] Cresswell P, Springer T, Strominger JL, et al. Immunological identity of the small subunit of HL-A antigens and beta2-microglobulin and its turnover on the cell membrane. Proc Natl Acad Sci U S A 1974;71:2123–7.
[19] Cooper EH, Plesner T. Beta-2-microglobulin review: its relevance in clinical oncology. Med Pediatr Oncol 1990;8:323–34.
[20] Turman MA, Bates CM. Susceptibility of human proximal tubular cells to hypoxia: effect of hypoxic preconditioning and comparison to glomerular cells. Ren Fail 1997;19:47–60.
[21] Yen MH, Tsao KC, Huang YC, et al. Viral load in blood is correlated with disease severity of neonatal coxsackievirus B3 infection: early diagnosis and predicting disease severity is possible in severe neonatal enterovirus infection. Clin Infect Dis 2007;44:78–81.
[22] Cheng HY, Huang YC, Yen TY, et al. The correlation between the presence of viremia and clinical severity in patients with enterovirus 71 infection: a multi-center cohort study. BMC Infect Dis 2014;14:417.
[23] Aizawa Y, Watanabe K, Oishi T, et al. Role of maternal antibodies in infants with severe diseases related to human parechovirus type 3. Emerg Infect Dis 2015;21:1966–72.
[24] Modlin JF, Poll B, Horton P, et al. Perinatal echovirus infection: risk of transmission during a community outbreak. N Engl J Med 1981;305:368–71.
[25] Nissen MH, Larsen JK, Plesner T, et al. Alpha-interferon induces enhanced expression of HLA-ABC antigens and beta-2-microglobulin in vivo and in vitro in various subsets of human lymphoid cells. Clin Exp Immunol 1987;69:632–8.
[26] Hara S, Kawada J, Kawano Y, et al. Hyperferritinemia in neonatal and infantile human parechovirus-3 infection in comparison with other infectious diseases. J Infect Chemother 2014;20:15–9.
[27] Fortuna D, Cardenas AM, Graf EH, et al. Human parechovirus and enterovirus initiate distinct CNS innate immune responses: Pathogenic and diagnostic implications. J Clin Virol 2017;86:39–45.
[28] Vollbach S, Muller A, Drexler JF, et al. Prevalence, type and cation by use of the VP4 sequence for direct identifica...